The ATTD (Advanced Technologies & Treatments for Diabetes) conference is a cornerstone event for the diabetes community, showcasing the latest advancements in diabetes technology and treatments. Today, we share about the Dexcom direct to Apple Watch connectivity and Roche’s AI-powered CGM.
ATTD is taking place March 6-9, 2024 in Florence Italy. Although the Connected in Motion Team has been lucky enough to attend in person in the past, this year we’re watching from afar! Luckily, we have friends on the ground who have been keeping us in the loop with the most exciting updates for the Type 1 diabetes community.
The Dexcom direct to Apple Watch connectivity announcement happened at ATTD for its G7 Continuous Glucose Monitor (CGM) system, marking a significant milestone in diabetes management technology. By enabling users to view their glucose levels directly on their wrist, Dexcom is not just enhancing convenience but also fostering greater independence and discretion in glucose monitoring. This development is particularly exciting for active individuals and tech-savvy users who seek to integrate health management seamlessly into their lifestyle. Word on the street is that the Dexcom direct to Apple Watch connectivity will be available in the US by the second quarter of 2024. Still no word on availability in Canada.
Meanwhile, Roche has unveiled its Accu-Chek SmartGuide CGM, which not only tracks glucose levels but also utilizes predictive AI to forecast future glucose trends. This device will be another option in the CGM world but is still investigational. It promises a 14-day wear time and requires initial calibration. We’ll be keeping an eye on this one as it moves through its trial phases and applies for approval in the future.
We’re excited to share more with you throughout the week as new tech and advancements are discussed at the ATTD conference. Keep an eye on our updates – and we’ll keep our finger on the pulse in Italy.
